F-star, a biotech company originally founded in Vienna but now mainly based in the UK, has appointed Neil Brewis as chief scientific officer. 2 November 2015
Producing drugs is an expensive business, and to help ensure the sustainability of such a business, drugmakers are granted patents that protect product innovations, writes Dr Nicola Davies in her monthly exclusive for The Pharma Letter. 26 October 2015
US health care giant Johnson & Johnson is set to launch its drug to treat multiple myeloma in 2016, pending regulatory approvals, Peter Lebowitz, head of global oncology, Janssen Pharmaceutical Companies of Johnson & Johnson, told The Pharma Letter in an interview at a London event. 23 October 2015
Basilea Pharmaceutica plans to start selling isavuconazole in Europe next year at a price modestly higher than the current market leader voriconazole, chief commercial officer David Veitch told The Pharma Letter in an interview. 19 October 2015
Biopharma company XenoPort has replaced its chief executive at a moment when the company is refocusing its strategic efforts, causing shares to rise 12%. 5 October 2015
The European Medicines Agency’s management board has nominated Guido Rasi as the executive director of the Agency. At an extraordinary session on October 1, the board selected Prof Rasi from a shortlist of candidates provided by the European Commission. 1 October 2015
"Prolonging life is the gold standard endpoint of any drug trial," Professor John Crown, consultant medical oncologist for St Vincent’s University Hospital told The Pharma Letter in an interview, as the Japanese pharmaceutical giant Eisai announced data for its clinical trials at the European Cancer Congress in Vienna. 30 September 2015
Ferring Pharma is looking at building a commercial as well as manufacturing headquarters in India over the next two-three years, chief operating officer Michael Pettigrew told The Pharma Letter in an interview. 24 September 2015
Ferring Pharma expects a 20% increase in 2015 full-year revenue on the back of a stronger US dollar, chief operating officer Michel Pettigrew, told The Pharma Letter in an interview. 23 September 2015
German company leon-nanodrugs has appointed Theron Odlaug as chief executive and the chief executive of its newly-formed US subsidiary. 22 September 2015
Contract research and manufacturing organization Albany Molecular Research has made George Svokos chief operating officer, and Lori Henderson head of corporate business development. 14 September 2015
EMD Serono, the biopharma division of German pharma company Merck, has appointed Scott Filosi as senior vice president of managed markets. 10 September 2015
Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. 14 August 2024
The shortage of drugs in Russia is deepening, and is currently being observed in almost 70 regions throughout the country and forcing the local state to consider ways to resume stable supplies to local market, reports The Pharma Letter’s local correspondent. 13 August 2024
US biotech major Biogen is disputing the launch of a Russian generic of Spinraza (nusinersen), a drug, which is used to treat spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. 7 August 2024
CytoReason’s $80 million venture round may not have been the biggest in July, but it is one of a growing number of investor bets on AI powered drug discovery this year. 7 August 2024
Domestic drugs and foreign drugs, the production of which is localized in Russia, will be given a priority when included in the list of vital and essential drugs (VED) and expensive drugs, according to a recent resolution signed by the Russian government, The Pharma Letter’s local correspondent reports. 1 August 2024